Response of Early Stage B-CLL to Interferon-α:2 Years Experience of a Pilot Study

  • R. Schlag
  • H. W. L. Ziegler-Heitbrock
  • D. Flieger
  • E. Thiel
Conference paper


Chronic lymphocytic leukemia of B cell-type (B-CLL) is looked upon as the most common form of leukemia in the western hemisphere. The prognosis varies from 6 months to 25 years. Cytoreductive therapy is usually restricted to patients with hemopoietic insufficiency or with progressive lymphomas. A major problem in these patients, however, is the complex immunodeficiency involving both humoral and cell-mediated immune responses. Cytotoxic regimen have to be used cautiously in order to avoid further deterioration of the immune defense [1]. Therefore, treatment with interferon (IFN) might be an alternative therapeutic strategy, acting in an antineoplastic way and stimulating the immune system at the same time.


Chronic Lymphocytic Leukemia Human Leukocyte Antigen Lymphocyte Count Chronic Lymphocytic Leukemia Patient Hairy Cell Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gale RP, Foon KA (1985) Chronic lymphocytic leukemia:recent advances in biology and treatment. Ann Intern Med 103:101–120PubMedGoogle Scholar
  2. 2.
    Caligaris-Cappio F, Janossy G (1985) Surface markers in chronic lymphoid leukemias of B-cell type. Semin Hematol 22:1–12PubMedGoogle Scholar
  3. 3.
    Ziegler-Heitbrock HWL, Munker R, Dörken B, Gaedicke G, Thiel E (1986) Induction of features characteristic of hairy celll leukemia in chronic lymphocytic leukemia and prolymphocyte leukemia cells. Cancer Res 46:2172–2178PubMedGoogle Scholar
  4. 4.
    Foon KA, Sherwin SA, Abrams PG (1984) Treatment of advanced non-Hodgkin’s lymphoma with recombinant leukocyte A interferon. N Engl J Med 311:1148–1152PubMedCrossRefGoogle Scholar
  5. 5.
    Schulof RS, Loyd MJ, Stallings JJ, Mai D, Philips TM, Jones GJ, Schechter GP (1985) Recombinant leukocyte A interferon in B-cell chronic lymphocytic leukemia:in vivo effects on autologous antitumor immunity. J Biol Response Mod 4:310–323PubMedGoogle Scholar
  6. 6.
    Leavitt RD, Ratanatharathorn V, Ozer H, Ultman JE, Portlock C, Myers JW, Kisner D, Norred S, Spiegel RJ, Bonnem EM (1987) Alfa-2b-interferon in the treatment of Hodgkin’s Disease and non-Hodgkin’s lymphoma. Semin Oncol [Suppl. 2] 14:18–23PubMedGoogle Scholar
  7. 7.
    O’Connell MJ, Colgan JP, Oken MM, Ritts RE, Kay ME, Itri LM (1986) Clinical trial of recombinant leukocyte A interferon as initial therapy for favourable histology non-Hodgkin’s lymphomas and chronic lymphocytic leukemia:an Eastern Cooperative Oncology Group pilot study. J Clin Oncol 4:128–136PubMedGoogle Scholar
  8. 8.
    Talpaz M (1987) Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia:a pilot study. Am J Hematol 24:341–350PubMedCrossRefGoogle Scholar
  9. 9.
    Pangalis GA, Griva E (1988) Recombinant alfa-2b-interferon therapy in untreated, stages A and B chronic lymphocytic leukemia. Cancer 61:869–872PubMedCrossRefGoogle Scholar
  10. 10.
    Rozman C, Montserrat E, Vinolas N, Urbano-Ispizua A, Ribera JM, Gallart T, Compernolle C (1988) Recombinant alfa-2-interferon in the treatment of B chronic lymphocytic leukemia in early stages. Blood 71:1295–1298PubMedGoogle Scholar
  11. 11.
    French Cooperative Group on Chronic Lymphocytic Leukemia (1986) Effectiveness of “CHOP” regimen in advanced untreated chronic lymphocytic leukemia. Lancet 1:1346–1349Google Scholar
  12. 12.
    Thiel E, Schlag R, Hill W, Kettner G, Flieger D, Ziegler HWL (1987) B-Cll in early phase responds to recombinant alpha-2b interferon therapy as determined in a pilot study (abstract). Blut 55:243Google Scholar
  13. 13.
    Ziegler-Heitbrock HWL, Schlag R, Flieger D, Thiel E (1989) Favourable response of early stage B-CLL patients to treatment with IFN-α2. Blood 73:1426–1430PubMedGoogle Scholar
  14. 14.
    Rosenberg SA (1985) The low-grade non-Hodgkin’s lymphomas:challenges and opportunities. J Clin Oncol 3:299–310PubMedGoogle Scholar
  15. 15.
    International Workshop on Chronic Lymphocytic Leukemia (1989) Chronic lymphocytic leukemia:recommendations for diagnosis, staging, and response criteria. Ann Int Med 110:236–238Google Scholar
  16. 16.
    Frisch B, Bartl R (1988) Histologic classification and staging of chronic lymphocytic leukemia. Acta Haematol 79:140–152PubMedCrossRefGoogle Scholar
  17. 17.
    Golomb HM, Jacobs A, Fefer A, Ozer H, Thompson J, Portlock C, Ratain M, Golde D, Cardiman J, Burke JS, Brady J, Vonnem E, Spiegel R (1986) Alpha-2 interferon therapy of hairy-cell leukemia:a multicenter study of 64 patients. J Clin Oncol 4:900–905PubMedGoogle Scholar
  18. 18.
    Catovsky D, Miliani E, Okos A, Galton DAG (1974) Clinical significance of T-cells in chronic lymphocytic leukemia. Lancet II:751CrossRefGoogle Scholar
  19. 19.
    Flieger D, Ziegler-Heitbrock HWL (1988) Abnormal blood monocytes in chronic lymphocytic leukemia. Cancer Res 48:4812PubMedGoogle Scholar
  20. 20.
    Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU (1984) Alpha interferon for induction of remission in hairy cell leukemia. N Eng J Med, 310:15CrossRefGoogle Scholar
  21. 21.
    Ratain MJ, Golomb HM, Vardiman JW, Vokes EE, Jacobs RH, Daly K (1985) Treatment of hairy cell leukemia with recombinant alpha-2 interferon. Blood 65:644PubMedGoogle Scholar
  22. 22.
    Thompson JA, Brady J, Kidd P, Fefer A (1985) Recombinant alpha-2 interferon in the treatment of hairy cell leukemia. Cancer Treat Rep 69:791PubMedGoogle Scholar
  23. 23.
    Jacobs AD, Champlin RE, Golde DW (1985) Recombinant α-2 interferon for hairy cell leukemia. Blood 65:1017PubMedGoogle Scholar
  24. 24.
    Foon KA, Maluish AE, Abrams PG, Wrightington S, Stevenson HC, Alarif A, Fer MF, Overton WR, Poole M, Schnipper EF, Jafe ES, Herberman RB (1986) Recombinant leukocyte A interferon therapy for advanced hairy cell leukemia. Am J Med 80:351PubMedCrossRefGoogle Scholar
  25. 25.
    Montserrat E, Sanchez-Bisano J, Vinolas N, Rozman C (1986) Lymphocyte doubling time in chronic lymphocytic leukemia:analysis of its prognostic significance. Br J Haematol 62:567–575PubMedCrossRefGoogle Scholar
  26. 26.
    Kempin S, Lee BJ, Thaler HT, Koziner B, Hecht S, Gee T, Arlin Z, Little C, Straus D, Reich L, Philips E, Al-Mondhiry H, Dowling M, Mayer K, Clarkson B (1982) Combination chemotherapy of advanced chronic lymphocytic leukemia:the M–2 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone). Blood 60:1110PubMedGoogle Scholar
  27. 27.
    Spear GT, Paulnock DM, Jordan RL, Meltzer DM, Merritt JA, Borden EC (1987) Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo b- interferon. Clin Exp Immunol 69:107PubMedGoogle Scholar
  28. 28.
    Quesada JR, Alexanian R, Hawkins M, Barlogie B, Borden E, Itri L, Gutterman JU (1986) Treatment of multiple myeloma with recombinant alpha-interferon. Blood 67:275–278PubMedGoogle Scholar

Copyright information

© Springer-Verlag, Berlin Heidelberg 1990

Authors and Affiliations

  • R. Schlag
  • H. W. L. Ziegler-Heitbrock
  • D. Flieger
  • E. Thiel

There are no affiliations available

Personalised recommendations